Ironwood Pharma (IRWD) Acquires Exclusive License with COUR Pharmaceuticals to Develop and Commercialize CNP-104 for the Treatment of Primary Biliary Cholangitis (PBC)
Go back to Ironwood Pharma (IRWD) Acquires Exclusive License with COUR Pharmaceuticals to Develop and Commercialize CNP-104 for the Treatment of Primary Biliary Cholangitis (PBC)| IRONWOOD PHARMA-A (NASDAQ: IRWD) | Delayed: 4.12 -0.14 (3.29%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $4.26 | 52 Week High | $16.89 | |||
| Open | $4.25 | 52 Week Low | $7.35 | |||
| Day High | $4.27 | P/E | N/A | |||
| Day Low | $4.08 | EPS | $-2.35 | |||
| Volume | 928,308 | |||||
